Investigational drug · Phase 3
DN022150
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Pancreatic Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "DN022150"
First trial start
2026
Sep 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DN022150", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Pancreatic Carcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DN022150" as an intervention, largest first.
- Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D MutationPivotal-lookingNot yet recruiting
Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
NCT07656376 · 465 participants (planned) · Start Jun 6, 2027 · Primary completion Feb 7, 2029
Drug: DN022150+AG( Stage I ); DN022150+AG(Stage II) and 1 more · For: Pancreatic Cancer; Pancreatic Carcinoma
- Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D MutationPivotal-lookingNot yet recruiting
Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
NCT07689539 · 360 participants (planned) · Start Sep 2026 · Primary completion Jul 2028
Drug: DN022150; Chemotherapy · For: Pancreatic Cancer
Newest research
PubMed records naming it or its code names, newest first.
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.
Pillozzi S, Giommoni E, Petroni G, et al. · J Hematol Oncol 2026
- The KRASG12D Inhibitor Pipeline Grows.
· Cancer Discov 2026
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.